The popularity of copyright’s blockbuster initially sparked a surge for pharma, however recent shifts present a uncertain scenario for shareholders. Generic competitors are reducing revenue, and persistent legal https://antonwqlw962089.blogsidea.com/47979021/the-blue-pill-and-the-pharmaceutical-industry-a-risky-bet